Rallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Buys 6,009 Shares

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc acquired 6,009 shares of the stock in a transaction on Monday, May 18th. The shares were purchased at an average price of $13.98 per share, with a total value of $84,005.82. Following the completion of the transaction, the insider owned 916,152 shares of the company’s stock, valued at approximately $12,807,804.96. This represents a 0.66% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, May 19th, Adar1 Capital Management, Llc acquired 10,200 shares of Rallybio stock. The shares were purchased at an average price of $13.98 per share, with a total value of $142,596.00.
• On Friday, May 15th, Adar1 Capital Management, Llc acquired 300 shares of Rallybio stock. The shares were purchased at an average price of $13.90 per share, with a total value of $4,170.00.
• On Wednesday, May 13th, Adar1 Capital Management, Llc acquired 79,259 shares of Rallybio stock. The shares were purchased at an average price of $13.99 per share, with a total value of $1,108,833.41.
• On Tuesday, May 12th, Adar1 Capital Management, Llc acquired 800 shares of Rallybio stock. The shares were purchased at an average price of $13.83 per share, with a total value of $11,064.00.
• On Monday, May 11th, Adar1 Capital Management, Llc bought 50,000 shares of Rallybio stock. The shares were bought at an average cost of $14.00 per share, for a total transaction of $700,000.00.
• On Tuesday, May 5th, Adar1 Capital Management, Llc bought 35,101 shares of Rallybio stock. The shares were bought at an average cost of $14.00 per share, for a total transaction of $491,414.00.
• On Monday, May 4th, Adar1 Capital Management, Llc bought 120,804 shares of Rallybio stock. The shares were bought at an average cost of $13.97 per share, for a total transaction of $1,687,631.88.

Rallybio Stock Performance

NASDAQ RLYB opened at $14.58 on Thursday. Rallybio Corporation has a fifty-two week low of $2.16 and a fifty-two week high of $15.31. The stock has a market cap of $77.27 million, a PE ratio of -3.20 and a beta of -1.10. The firm’s fifty day moving average price is $10.05 and its two-hundred day moving average price is $7.25.

Rallybio (NASDAQ:RLYB) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.26). Rallybio had a negative return on equity of 55.79% and a negative net margin of 911.07%.The business had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.21 million.

Analyst Ratings Changes

RLYB has been the topic of several analyst reports. Wall Street Zen raised shares of Rallybio to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Rallybio in a report on Friday, May 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Rallybio

A number of institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC boosted its holdings in shares of Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after buying an additional 120,892 shares in the last quarter. Citadel Advisors LLC boosted its holdings in shares of Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after buying an additional 373,821 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Rallybio by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after purchasing an additional 2,996 shares in the last quarter. Susquehanna International Group LLP boosted its position in shares of Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after purchasing an additional 113,031 shares in the last quarter. Finally, XTX Topco Ltd grew its stake in shares of Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after buying an additional 38,205 shares during the period. 90.34% of the stock is currently owned by institutional investors.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.